Linda was too smart to get caught in that trap. Easier to leverage a U.S. approval from where rational thought and suffering patients are actually being prioritized albeit slowly. No sense risking being caught in a subjective decision process that refuses to elevate common sense and is easily influenced by big pharma tentacles. Fortunately that reach is slowly eroding as of this year since big pharma reps won’t be sitting on advisory boards with voting privileges as a regular practice but rather more as an exception. Baby steps. Best wishes.
Market Data 
Markets 
AI
